ENANTA PHARMACEUTICALS INC's ticker is ENTA and the CUSIP is 29251M106. A total of 199 filers reported holding ENANTA PHARMACEUTICALS INC in Q3 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2018 | $31,000 | – | 350 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Krensavage Asset Management, LLC | 564,102 | $42,184,000 | 14.63% |
| Fairmount Funds Management LLC | 387,400 | $28,970,000 | 9.55% |
| Soleus Capital Management, L.P. | 318,275 | $23,801,000 | 2.38% |
| Darwin Global Management, Ltd. | 166,190 | $12,428,000 | 1.90% |
| Paradigm Biocapital Advisors LP | 75,507 | $5,646,000 | 1.61% |
| ARMISTICE CAPITAL, LLC | 1,056,000 | $78,968,000 | 1.29% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 150,000 | $11,217,000 | 1.29% |
| Portland Global Advisors LLC | 75,869 | $5,673,000 | 0.95% |
| FARALLON CAPITAL MANAGEMENT LLC | 1,573,829 | $117,691,000 | 0.59% |
| Yorktown Management & Research Co Inc | 10,400 | $778,000 | 0.52% |